Comparison of oral propranolol and verapamil for combined systemic hypertension and angina pectoris
| Autor: | Joel A. Strom, William H. Frishman, Robert Tawil, Simcha Pollack, Steven Roth, Neal Klein, Thierry H. LeJemtel, Edmund H. Sonnenblick, Philip Klein, Bowen Wong, Roger K. Strair |
|---|---|
| Rok vydání: | 1982 |
| Předmět: |
medicine.medical_specialty
Aldosterone business.industry Propranolol medicine.disease Placebo Crossover study Plasma renin activity Angina chemistry.chemical_compound Blood pressure chemistry Internal medicine Anesthesia medicine Cardiology Verapamil Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | The American Journal of Cardiology. 50:1164-1172 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/0002-9149(82)90438-6 |
| Popis: | The relative efficacies of oral verapamil, a calcium-entry blocking drug, and propranolol, a beta-adrenergic blocking drug, were compared in 12 patients who had both stable angina pectoris and mild to moderate systemic hypertension, using a placebo-controlled, double-blind, randomized crossover protocol. Compared with placebo, both propranolol and verapamil decreased the frequency of anginal attacks and the number of nitroglycerin tablets consumed, and increased exercise duration and total work; there were no significant differences in the antianginal effect of the two drugs. Both verapamil and propranolol reduced the supine and standing systolic and diastolic blood pressure measured at rest; compared with propranolol, however, verapamil had greater effects on standing diastolic blood pressure (p less than 0.002). Resting heart rate was reduced from placebo baseline with large doses of both drugs; compared with verapamil, however, propranolol exerted greater effects on resting heart rate and rate-pressure product. Plasma renin activity was increased from placebo baseline with verapamil (p less than 0.05), but was reduced with propranolol (p less than 0.05); no significant change in plasma aldosterone was seen with either drug. Verapamil appears to be a safe and effective treatment alternative to propranolol for relieving anginal symptoms, improving exercise tolerance, and reducing elevated systemic blood pressure in patients with both angina pectoris and mild to moderate systemic hypertension. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|